19 results
424B5
ELTX
Elicio Therapeutics Inc.
24 May 22
Prospectus supplement for primary offering
4:02pm
volunteer study, which was designed to support clinical development in multiple indications, demonstrated ANG-3070 has a favorable safety and PK
424B3
ELTX
Elicio Therapeutics Inc.
24 May 22
Prospectus supplement
4:01pm
in a variety of animal models. A Phase 1 healthy volunteer study, which was designed to support clinical development in multiple indications
S-3
ELTX
Elicio Therapeutics Inc.
16 May 22
Shelf registration
5:23pm
in a variety of animal models. A Phase 1 healthy volunteer study, which was designed to support clinical development in multiple indications, demonstrated ANG … models. A Phase 1 healthy volunteer study, which was designed to support clinical development in multiple indications, demonstrated ANG-3070 has
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
30 Mar 22
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
4:52pm
detail positive data from the Phase 1 healthy volunteer study of ANG-3070
◦Presented preclinical data in several models of kidney and lung fibrosis
8-K
EX-99.1
kflf6kyo oci76c7
12 Nov 21
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
r6jfv
12 Aug 21
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
4:10pm
8-K
EX-99.1
0jzj5zmbj 4k
17 May 21
Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results
6:20am
10-Q
m58dh564k
17 May 21
Quarterly report
6:03am
8-K
EX-99.1
ig370cmz n1g4t
30 Mar 21
Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
5:02pm
10-K
r4gzd0b4
30 Mar 21
Annual report
5:00pm
424B4
p9gjr3wkkehjpoo9a
5 Feb 21
Prospectus supplement with pricing info
5:12pm
DRS/A
cawqaq08
15 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
hmiz4i1y1kgo5jyx
13 May 20
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next